<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30120164</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>18</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1549-490X</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>17</Day>                    </PubDate>                </JournalIssue>                <Title>The oncologist</Title>                <ISOAbbreviation>Oncologist</ISOAbbreviation>            </Journal>            <ArticleTitle>Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">theoncologist.2018-0200</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1634/theoncologist.2018-0200</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Breast cancer (BC) is one of the solid tumors most commonly associated with leptomeningeal disease (LMD). LMD carries a devastating prognosis; however, disease presentation and prognostic factors are uncertain.</AbstractText>                <AbstractText Label="SUBJECTS, MATERIALS, AND METHODS" NlmCategory="UNASSIGNED">In order to describe patient characteristics, treatment patterns, and factors associated with survival in a contemporary multicentric cohort, 153 consecutive BC patients diagnosed with LMD at two European institutions (2002-2017) were included. Time to LMD and overall survival (OS) after LMD diagnosis were evaluated using the Kaplan-Meier method and Cox proportional hazards models.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Median age at LMD diagnosis was 58 years (25-84). Tumor phenotype distribution was as follows: hormone receptor (HR) positive (HR+)/human epidermal growth receptor 2 (HER2) negative 51.0%, triple-negative 15.0%, HR+/HER2 positive (HER2+) 13.1% and HR negative/HER2+ 7.2%. Most patients received active anticancer treatments (radiation therapy [RT] <i>n</i> = 42, systemic therapy <i>n</i> = 110, intrathecal treatment <i>n</i> = 103).Median OS was 3.9 months (95% confidence interval [CI] 2.4-5.5). Eastern Cooperative Oncology Group performance status (ECOG PS) &gt;2, high white blood cells count, low glucose, and high protein in cerebrospinal fluid (CSF) were poor prognostic factors. Having received RT or systemic treatment was associated with better prognosis. In multivariate analysis, ECOG PS (hazard ratio 2.22, 95% CI 1.25-3.94), CSF glucose levels (hazard ratio 1.74, 95% CI 1.05-2.88), and having received systemic treatment (hazard ratio 0.17, 95% CI 0.09-0.32) were confirmed as independent prognostic factors. In HER2+ BC patients, having received systemic HER2-targeted therapy was the only factor maintaining independent prognostication (hazard ratio 0.12, 95% CI 0.02-0.67) in multivariate analysis.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Despite being limited by their retrospective nature, these results highlight the need for clinical trials in BC LMD, stratified on tumor biology.</AbstractText>                <AbstractText Label="IMPLICATIONS FOR PRACTICE" NlmCategory="CONCLUSIONS">Leptomeningeal disease (LMD) is a devastating complication of breast cancer (BC), and its optimal therapy is still not defined. Here, patient characteristics, treatment patterns, and prognostic factors from a contemporary cohort of 153 BC-related LMD patients are reported. In multivariate analysis, Eastern Cooperative Oncology Group performance status, cerebrospinal fluid glucose levels, and having received systemic treatment were confirmed as independent prognostic factors in the overall population, whereas in human epidermal growth receptor 2 (HER2) positive BC patients, having received systemic HER2-targeted therapy was the only factor maintaining independent prognostication in multivariate analysis. These results highlight the need to consider stratification on tumor biology in the treatment of BC LMD.</AbstractText>                <CopyrightInformation>© AlphaMed Press 2018.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Griguolo</LastName>                    <ForeName>Gaia</ForeName>                    <Initials>G</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-8782-4509</Identifier>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Oncology and GastroenterologyUniversity of Padova, Padova, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pouderoux</LastName>                    <ForeName>Stephane</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Departments of Medical Oncology, Institut Régional du Cancer de Montpellier (ICM), Montpellier, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dieci</LastName>                    <ForeName>Maria Vittoria</ForeName>                    <Initials>MV</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Oncology and GastroenterologyUniversity of Padova, Padova, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jacot</LastName>                    <ForeName>William</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Departments of Medical Oncology, Institut Régional du Cancer de Montpellier (ICM), Montpellier, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bourgier</LastName>                    <ForeName>Céline</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Radiation Oncology, Institut Régional du Cancer de Montpellier (ICM), Montpellier, France.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institut de Recherche en Cancérologie de Montpellier INSERM U1194, Université de Montpellier, ICM, Montpellier, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Miglietta</LastName>                    <ForeName>Federica</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Oncology and GastroenterologyUniversity of Padova, Padova, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Firmin</LastName>                    <ForeName>Nelly</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Departments of Medical Oncology, Institut Régional du Cancer de Montpellier (ICM), Montpellier, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Conte</LastName>                    <ForeName>Pierfranco</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy pierfranco.conte@unipd.it.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Oncology and GastroenterologyUniversity of Padova, Padova, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Viala</LastName>                    <ForeName>Marie</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Departments of Medical Oncology, Institut Régional du Cancer de Montpellier (ICM), Montpellier, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Guarneri</LastName>                    <ForeName>Valentina</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Oncology and GastroenterologyUniversity of Padova, Padova, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Darlix</LastName>                    <ForeName>Amélie</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Departments of Medical Oncology, Institut Régional du Cancer de Montpellier (ICM), Montpellier, France.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>17</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Oncologist</MedlineTA>            <NlmUniqueID>9607837</NlmUniqueID>            <ISSNLinking>1083-7159</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Human epidermal growth receptor 2</Keyword>            <Keyword MajorTopicYN="N">Leptomeningeal disease</Keyword>            <Keyword MajorTopicYN="N">Prognosis</Keyword>            <Keyword MajorTopicYN="N">Treatment</Keyword>        </KeywordList>        <CoiStatement>Disclosures of potential conflicts of interest may be found at the end of this article.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>04</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>06</Month>                <Day>11</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>19</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>19</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>19</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30120164</ArticleId>            <ArticleId IdType="pii">theoncologist.2018-0200</ArticleId>            <ArticleId IdType="doi">10.1634/theoncologist.2018-0200</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>